Decentralised clinical trials market to reach $21.34b by 2030

It is driven by rising digital adoption in pharma and biotech research.

The decentralised clinical trials (DCTs) market is projected to grow from $9.63b in 2024 to $21.34b by 2030, at a CAGR of 14.16%, according to ResearchAndMarkets.com.

This growth is driven by the pharmaceutical and biotechnology industries adopting digital solutions like wearable devices, telemedicine, and mobile apps for remote patient monitoring and data collection.

The rising demand for faster drug development and cost-effective trial solutions has made DCTs an attractive alternative to traditional models. These trials significantly reduce recruitment timelines and operational expenses, making the process more efficient.

Additionally, advancements in digital health technologies and telemedicine have improved trial logistics, ensuring broader patient participation and real-world evidence collection.

Despite their advantages, DCTs face challenges, particularly in regulatory compliance and data security. Existing regulations are often tailored to traditional trial models, requiring adaptation to accommodate digital and remote methodologies.

Moreover, concerns regarding patient privacy and the security of electronic health records pose risks as cyber threats become more prevalent.